vs
Side-by-side financial comparison of Sunshine Biopharma Inc. (SBFM) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
TRANSACT TECHNOLOGIES INC is the larger business by last-quarter revenue ($11.5M vs $8.6M, roughly 1.3× Sunshine Biopharma Inc.). On growth, TRANSACT TECHNOLOGIES INC posted the faster year-over-year revenue change (11.9% vs -10.6%). TRANSACT TECHNOLOGIES INC produced more free cash flow last quarter ($589.0K vs $-1.6M). Over the past eight quarters, Sunshine Biopharma Inc.'s revenue compounded faster (6.6% CAGR vs 3.5%).
Sunshine Biopharma Inc. is a clinical-stage biopharmaceutical company focused on researching, developing and commercializing innovative therapies for oncology, neurodegenerative disorders and infectious diseases. It targets unmet medical needs across global markets, with a pipeline of targeted therapeutic candidates designed to improve patient treatment outcomes.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
SBFM vs TACT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.6M | $11.5M |
| Net Profit | $-2.1M | — |
| Gross Margin | 35.3% | 47.6% |
| Operating Margin | -20.9% | -10.1% |
| Net Margin | -25.0% | — |
| Revenue YoY | -10.6% | 11.9% |
| Net Profit YoY | 0.8% | — |
| EPS (diluted) | — | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.6M | $11.5M | ||
| Q3 25 | $9.4M | $13.2M | ||
| Q2 25 | $9.4M | $13.8M | ||
| Q1 25 | $8.9M | $13.1M | ||
| Q4 24 | $9.6M | $10.2M | ||
| Q3 24 | $8.4M | $10.9M | ||
| Q2 24 | $9.3M | $11.6M | ||
| Q1 24 | $7.5M | $10.7M |
| Q4 25 | $-2.1M | — | ||
| Q3 25 | $-883.8K | $15.0K | ||
| Q2 25 | $-1.8M | $-143.0K | ||
| Q1 25 | $-1.2M | $19.0K | ||
| Q4 24 | $-2.2M | — | ||
| Q3 24 | $-1.2M | $-551.0K | ||
| Q2 24 | $-494.3K | $-319.0K | ||
| Q1 24 | $-1.3M | $-1.0M |
| Q4 25 | 35.3% | 47.6% | ||
| Q3 25 | 32.6% | 49.8% | ||
| Q2 25 | 36.4% | 48.2% | ||
| Q1 25 | 30.7% | 48.7% | ||
| Q4 24 | 32.2% | 44.2% | ||
| Q3 24 | 34.0% | 48.1% | ||
| Q2 24 | 25.3% | 52.7% | ||
| Q1 24 | 31.2% | 52.6% |
| Q4 25 | -20.9% | -10.1% | ||
| Q3 25 | -11.5% | 0.1% | ||
| Q2 25 | -21.8% | -1.9% | ||
| Q1 25 | -14.6% | -0.1% | ||
| Q4 24 | -21.7% | -10.3% | ||
| Q3 24 | -13.1% | -7.7% | ||
| Q2 24 | -13.6% | -3.8% | ||
| Q1 24 | -17.9% | -12.2% |
| Q4 25 | -25.0% | — | ||
| Q3 25 | -9.4% | 0.1% | ||
| Q2 25 | -18.8% | -1.0% | ||
| Q1 25 | -13.3% | 0.1% | ||
| Q4 24 | -22.5% | — | ||
| Q3 24 | -14.2% | -5.1% | ||
| Q2 24 | -5.3% | -2.8% | ||
| Q1 24 | -17.0% | -9.7% |
| Q4 25 | — | $-0.11 | ||
| Q3 25 | $-0.54 | $0.00 | ||
| Q2 25 | $-0.82 | $-0.01 | ||
| Q1 25 | $-0.44 | $0.00 | ||
| Q4 24 | $49.77 | $-0.80 | ||
| Q3 24 | $-11.61 | $-0.06 | ||
| Q2 24 | $-43.48 | $-0.03 | ||
| Q1 24 | $-2.00 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $23.0M | $31.1M |
| Total Assets | $30.1M | $44.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $20.4M | ||
| Q3 25 | — | $20.0M | ||
| Q2 25 | — | $17.7M | ||
| Q1 25 | — | $14.2M | ||
| Q4 24 | — | $14.4M | ||
| Q3 24 | — | $11.3M | ||
| Q2 24 | — | $11.1M | ||
| Q1 24 | — | $10.6M |
| Q4 25 | $23.0M | $31.1M | ||
| Q3 25 | $24.2M | $31.8M | ||
| Q2 25 | $25.7M | $31.3M | ||
| Q1 25 | $22.7M | $30.9M | ||
| Q4 24 | $23.5M | $30.6M | ||
| Q3 24 | $25.0M | $38.4M | ||
| Q2 24 | $23.5M | $38.5M | ||
| Q1 24 | $24.8M | $38.6M |
| Q4 25 | $30.1M | $44.8M | ||
| Q3 25 | $31.5M | $45.0M | ||
| Q2 25 | $32.0M | $44.5M | ||
| Q1 25 | $29.2M | $44.2M | ||
| Q4 24 | $30.6M | $44.0M | ||
| Q3 24 | $30.1M | $50.5M | ||
| Q2 24 | $29.3M | $50.4M | ||
| Q1 24 | $31.9M | $51.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.6M | $609.0K |
| Free Cash FlowOCF − Capex | $-1.6M | $589.0K |
| FCF MarginFCF / Revenue | -18.9% | 5.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-5.5M | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.6M | $609.0K | ||
| Q3 25 | $-727.8K | $3.6M | ||
| Q2 25 | $-1.3M | $3.6M | ||
| Q1 25 | $-1.7M | $-161.0K | ||
| Q4 24 | $-3.4M | $2.4M | ||
| Q3 24 | $-1.4M | $327.0K | ||
| Q2 24 | $-4.6M | $636.0K | ||
| Q1 24 | $-3.2M | $-1.5M |
| Q4 25 | $-1.6M | $589.0K | ||
| Q3 25 | $-735.8K | $3.6M | ||
| Q2 25 | $-1.4M | $3.6M | ||
| Q1 25 | $-1.7M | $-171.0K | ||
| Q4 24 | $-3.5M | $2.4M | ||
| Q3 24 | $-1.9M | $259.0K | ||
| Q2 24 | $-5.6M | $499.0K | ||
| Q1 24 | $-3.2M | $-1.6M |
| Q4 25 | -18.9% | 5.1% | ||
| Q3 25 | -7.8% | 27.1% | ||
| Q2 25 | -15.2% | 25.9% | ||
| Q1 25 | -19.3% | -1.3% | ||
| Q4 24 | -36.6% | 23.2% | ||
| Q3 24 | -22.2% | 2.4% | ||
| Q2 24 | -59.7% | 4.3% | ||
| Q1 24 | -43.1% | -14.9% |
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.1% | 0.5% | ||
| Q2 25 | 1.7% | 0.1% | ||
| Q1 25 | 0.1% | 0.1% | ||
| Q4 24 | 1.1% | 0.1% | ||
| Q3 24 | 6.1% | 0.6% | ||
| Q2 24 | 10.5% | 1.2% | ||
| Q1 24 | 0.8% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
